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INTRODUCTION
The hematologic and immunologic changes associated
with bone marrow transplantation (BMT) increase the risk
of acquiring a host of potentially life-threatening infections
during and after the pro c e d u re. A particular problem fol-
lowing BMT is Pneumocystis carinii pneumonia (PCP),
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ABSTRACT
Pneumocystis carinii pneumonia (PCP) is a life-threatening but preventable infection that may occur after bone mar-
row transplantation (BMT). Although various prophylactic regimens have been used in this setting to prevent active
infection, their effic a c y, toxicity pro file, and impact on outcomes are poorly described in this patient group. We
u n d e rtook a re t rospective cohort study in which we reviewed the re c o rds of 451 adult patients who underw e n t
BMT for hematologic malignancies, aplastic anemia, or myelodysplasia over a 7-year period at the Brigham and
Wo m e n ’s Hospital. Post-BMT PCP prophylaxis consisted of aerosolized pentamidine (AP) 150 mg every 2 weeks or
300 mg per month, trimethoprim/sulfamethoxazole (TMP/SMX) 160/800 mg orally b.i.d. 3 times per week, or dap-
sone 100 mg orally each day. Prophylaxis was continued for 1 year post-BMT in all patients when clinically feasible.
One hundred twenty-one patients were unevaluable because of death or relapse <60 days after BMT (n589), loss to
follow-up upon hospital discharge (n 5 20), or other reasons (n 5 12). Three eligible patients did not receive any
p rophylaxis and were not further evaluated. Of the 327 patients analyzed, 133 underwent autologous BMT, 4 syn-
geneic BMT, 159 related allogeneic BMT, and 31 unrelated allogeneic BMT. Graft-versus-host disease prophylaxis in
the 190 patients receiving allogeneic BMT consisted of T-cell depletion with anti-CD5 and complement in 58 p a t i e n t s
and cyclosporine/methotrexate or FK506 with or without steroids in 132 patients. Eight of 327 (2.4%) documented
PCP cases were identified, 0 of 105 in patients receiving only TMP/SMX. Four cases occurred in patients re c e i v i n g
only AP (4/44, 9.1%; odds ratio [OR] relative to TMP/SMX 23.4, 95% confidence interval [CI] 1.2, 445.2); 1 in
patients receiving only dapsone (1/31, 3.2%; OR not significant); 2 in patients receiving more than 1 pro p h y l a c t i c
regimen (2/147 1.4%; OR not significant); and 1 .1 year post-BMT in a patient who was off PCP pro p h y l a x i s .
Although the patients receiving only AP had a significantly lower probability of tre a t m e n t - related toxicity than those
receiving TMP/SMX (OR 0.19 [95% CI 0.04, 0.85]), the probability of their acquiring other serious non-PCP i n f e c-
tions was increased (OR 2.2 [95% CI 1.0, 4.6]), and the probability of their dying by 1 year post-BMT was signifi-
cantly higher (OR 5.2 [95% CI 2.4, 26.6]), even when adjusted for variables such as type of BMT (autologous versus
allogeneic; high versus low risk) and sex. Although AP is associated with fewer toxicities, the data show that it is
inferior to TMP/SMX in preventing PCP in the post-BMT setting and is associated with an increased risk of other
infections and a higher mortality at 1 year after BMT.
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which, without prophylaxis, affects 5% to 15% of patients
within 1 year of transplantation [1]. The infection may be
fatal in two-thirds of cases. With prophylaxis, however, only
~1% of BMT patients develop PCP [2] .
In 1977, Hughes et al. first re p o rted that trimethoprim-
sulfamethoxazole (TMP/SMX) was an effective pro p h y l a c t i c
agent for PCP in children with cancer [3]. Subsequently, dap-
sone and aerosolized pentamidine (AP) have been shown to be
useful in preventing PCP in patients with human immunode-
ficiency virus (HIV) infection as well as in patients underg o i n g
solid organ transplantation [4-6]. Several comparison studies
have shown TMP/SMX to be more efficacious than other
agents in preventing PCP in HIV-positive patients [7-9],
although toxicities were more frequent [8]. Single-arm studies
in HIV-positive patients have also confirmed AP as an eff e c-
tive agent in preventing PCP, with minimal toxicities [10].
In BMT patients, all 3 drugs have been administered as
p r i m a ry prophylaxis, yet none has demonstrated a clear supe-
r i o r i t y. Furt h e rm o re, the toxicity pro file in this patient popu-
lation is largely unexplored. TMP/SMX has become the
s t a n d a rd prophylactic treatment after BMT, in large part
based on data from other patient groups [3]. However,
TMP/SMX may cause bone marrow suppression or delay
bone marrow engraftment following BMT [11-13] and is
associated with other adverse effects such as nausea and rash.
Dapsone, which does not cause myelosuppression, may be
used in patients intolerant of TMP/SMX. Adverse effects of
dapsone include hemolytic anemia and rash. AP may be bet-
ter tolerated in some patients and also does not cause bone
m a rrow suppression. However, AP is more costly to adminis-
ter than oral therapies, may cause bronchospasm or dyspnea,
and has been associated with atypical manifestations of infec-
tion, such as apical pneumonia or extrapulmonary disease
[14]. Thus, we conducted a re t rospective study to compare
the effectiveness and toxicities of TMP/SMX, AP, and dap-
sone as primary prophylaxis against PCP in patients follow-
ing BMT. We also examined outcomes with respect to over-
all survival and risk of graft-versus-host disease (GVHD) and
non-PCP infection in patient groups treated with 1 or a
combination of prophylactic re g i m e n s .
PATIENTS AND METHODS
Study P o p u l a t i o n
We conducted a re t rospective cohort study, re v i e w i n g
the re c o rds of 451 consecutive patients who underw e n t
BMT for a variety of hematologic malignancies at the
Brigham and Wo m e n ’s Hospital (BWH) over a 7-year
period (January 1, 1986 through December 31, 1993).
Patients who died or relapsed from their underlying disease
,60 days after BMT (n 5 89) were excluded from analysis.
Because PCP prophylaxis routinely begins 30 days after
B M T, ,30 days of follow-up was deemed inadequate for
meaningful evaluation. Furt h e rm o re, no case of P carinii i n f e c-
tion has ever been documented at our institution ,60 d a y s
after BMT, presumably because of TMP/SMX prophylaxis
during administration of the conditioning regimen pre -
B M T. Of the remaining cohort of 362 patients, 32 were
excluded from analysis for one of the following re a s o n s :
intravenous pentamidine administered as P n e u m o c y s t i s
p rophylaxis (n 5 8); trimethoprim alone administered as
P n e u m o c y s t i s p rophylaxis for 11 days before death (n 5 1 ) ;
refractory disease present during BMT (n 5 1); serologically
positive for HIV at the time of BMT (n 5 1); underw e n t
BMT at another institution but received follow-up care at
BWH (n 5 1); lost to follow-up immediately upon discharge
from BMT (n 5 20). (For the 20 patients lost to follow-up,
every effort was taken to secure information regarding their
c a re after BMT, including review of the patients’ ambula-
tory medical records, and, if applicable, post-BMT inpatient
admission re c o rds and discharge summaries and re c o rd s
from referring clinicians.) Thus, 330 patients form the basis
of this report. Of these, 3 did not receive PCP prophylaxis
and thus were not further analyzed.
Study Design
The medical re c o rds of all evaluable patients were
reviewed from the time of BMT admission through Decem-
ber 31, 1994 or until a clinical endpoint (defined below) was
reached. The following data re g a rding each patient were
re c o rded: demographics; indication for and type of BMT
p e rf o rmed, including conditioning regimen and GVHD
p rophylaxis (if applicable); type and duration of PCP pro-
phylaxis agents administered, along with associated toxici-
ties; presence and severity of GVHD; development of other
infections following reinstitution of prophylaxis after BMT;
and cause of death, if applicable.
A c c o rding to protocol at our institution, all patients were
t reated on days –6 to 0 pre-BMT with TMP/SMX (160 mg
and 800 mg, respectively) twice a day. On day 30 after BMT,
PCP prophylaxis was reinitiated with 1 of the following re g i-
mens: TMP/SMX at the doses specified twice a day every
M o n d a y, We d n e s d a y, and Friday; dapsone 100 mg daily; or
AP 300 mg monthly or 150 mg twice a month. Pro p h y l a x i s
was continued for 1 year post-BMT in the absence of
c h ronic GVHD. For patients treated at BWH, pentamidine
was dissolved in 3 mL sterile water and aerosolized over $2 0
minutes with either an Aerotech II or Respirg u a rd nebu l i z e r
linked to a compressed air source with an airflow of 8
L/min. Patients treated off site were given AP in a similar
fashion. Fre q u e n t l y, because of delayed bone marro w
engraftment, patients were treated with a single dose of AP
just before discharge from the hospital on or before day 30
post-BMT or began dapsone on day 30. At the patients’ fol-
low-up visits, either these agents were continued or, in the
setting of improving peripheral blood counts and at the dis-
c retion of the treating physician, the prophylaxis re g i m e n
was changed to TMP/SMX. In the latter scenario, tre a t m e n t
with AP was documented from day 30 to the date a new re g i-
men was initiated, even if this date was less than the 30 days
of prophylaxis expected from the most recent dose of AP.
The clinical decision re g a rding whether to switch a
patient to TMP/SMX was affected by 2 virtually simultane-
ous events in 1992. First, new data regarding the HIV-posi-
tive patient population suggested that AP was inferior to
TMP/SMX as primary P n e u m o c y s t i s p rophylaxis [8]. At the
same time, anecdotally at our institution, there was concern
that PCP was being diagnosed with increased frequency in
patients treated with AP alone. Thus, before 1992, if
patients tolerated their initial prophylaxis without complica-
tions, it was often continued. After 1992, a greater effort was
made to treat patients with TMP/SMX. 
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All patients with chronic GVHD persisting beyond 1 year
after BMT continued on P n e u m o c y s t i s p rophylaxis unless
specifically documented to the contrary by the tre a t i n g
physician. If a patient was switched from 1 pro p h y l a c t i c
t reatment regimen to another and the exact date was not
documented, then the median date between the 2 closest
dates documenting a particular prophylactic regimen sur-
rounding the switch was recorded as the switch date.
Definition of T e r m s
Diagnosis of PCP infection re q u i red microbiologic or
histopathologic verification based on positive toluidine
blue, methenamine silver, immunofluorescence staining of
induced sputum or bronchoalveolar lavage (BAL) fluid, or
identification of P carinii cysts on transbronchial or open
lung biopsy specimens in the context of an appropriate clin-
ical setting—that is, radiographic evidence of pneumonia in
a patient with cough, fever, hypoxemia, or dyspnea. Thir-
teen cases of pneumonia were identified in which P carinii
was suspected as the etiologic agent by the clinician(s)
t reating the patient, but no laboratory evidence of infection
by P n e u m o c y s t i s, or any other organism, was documented. In
these cases, patients were routinely treated empirically with
a wide range of antibiotics, including treatment specific for
P carinii infection. Given the uncertainty of these cases,
they are not included in our analysis as documented cases of
P C P, re g a rdless of the level of clinical suspicion on the part
of the treating physicians.
Infections following BMT were re c o rded if they
occurred at any point from the time a patient initiated pro-
phylaxis until a clinical endpoint, as defined subsequently,
was reached. Any infection that was deemed clinically re l evant
by the treating clinician was included. Non-PCP infections
were categorized into 4 groups: viral, fungal, bacterial, and
non-PCP pneumonia. Viral infections included those caused
by Va r i c e l l a - z o s t e r, Herpes simplex, Epstein-Barr, and
c y t o m e g a l o v i rus viruses (VZV, HSV, EBV, and CMV),
re g a rdless of the degree of clinical severity (e.g., der-
matomal VZV and CMV encephalitis were both included).
Similarly, fungal infections (comprised primarily of Candida
infections) were recorded whether they were localized (e.g.,
C a n d i d a esophagitis) or not. Bacterial infections included
b a c t e remia, Clostridium diff i c i l e e n t e rocolitis, and localized
infections involving, for example, the skin or soft tissue.
Pneumonia was categorized as a non-PCP pneumonia if the
etiologic agent was not clearly identified by sputum or blood
culture, serologic evaluation, or tissue diagnosis. Most cases
in this category were treated empirically and clinically
responded to antibiotics, suggesting a bacterial etiology. 
Toxicity of a prophylactic regimen was defined as any
adverse event that necessitated discontinuation of that par-
ticular medication and was reasonably likely to be related to
the prophylactic agent in the view of the treating physician.
Clinical Endpoints
Patients were followed until one of the following end-
points was reached: death, relapse, loss to follow-up, or end
of the study review period (31 December 1994). Patients
who developed documented PCP infection were followed
for clinical endpoints if they recovered from their infection;
h o w e v e r, secondary P n e u m o c y s t i s p rophylaxis was not
recorded. All patients were followed for at least 1 year after
BMT in the absence of 1 of the other clinical endpoints.
Statistical Anal y s i s
Patients were placed into 1 of 4 groups based on the
PCP prophylactic regimen they received: AP, dapsone,
TMP/SMX, or more than 1 regimen. Univariate analyses
using the Cochran-Mantel-Haenszel test [15] were per-
f o rmed to determine the patient characteristics that were
associated with the following clinical outcomes: GVHD,
non-PCP infection, active PCP infection, mortality at 1 y e a r
p o s t - B M T, and prophylaxis-associated toxic ity. The
patient characteristics included as variables were age at
the time of BMT; ethnic origin; sex; BMT type (autolo-
gous/syngeneic, related-donor allogeneic, unre l a t e d - d o n o r
allogeneic [URD]); P n e u m o c y s t i s p rophylactic regimen as
d e fined above; and high-risk BMT. High-risk patients were
defined as those undergoing BMT for myelodysplasia
(MDS) or acute lymphoblastic or myelogenous leukemia
(ALL or AML) in relapse or other than first complete
remission. The number of days on a prophylactic re g i m e n
was also included as a variable for all outcomes except pro-
phylaxis-associated toxicity, chronic GVHD, and surv i v a l
status at 1 year post-BMT. The definition for pro p h y l a x i s -
associated toxicity (see above) was directly correlated with
this variable. Similarly, the presence of chronic GVHD was
the only clinical scenario in which P n e u m o c y s t i s p ro p h y l a x i s
was extended beyond 1 year post-BMT. A stepwise logistic
re g ression pro c e d u re [16] was used to evaluate the associa-
tion between the 4 prophylaxis groups and all outcomes
except PCP infection, adjusting for potential confounders.
Because of numerical problems, the logistic re g re s s i o n
model was not fitted for PCP infections. In this analysis,
the odds of acquiring PCP were computed separately for
the transplant type and prophylaxis group combin a t i o n s .
Variables entered into the model only if their P value was
#0.15. Odds ratios (OR) are re p o rted along with their 95%
confidence intervals (CIs) in comparing the outcomes for
the 4 prophylaxis groups. Survival curves were generated by
methods of Kaplan-Meier [17].
RESULTS
The characteristics of the 327 patients analyzed in this
re p o rt are outlined in Table 1. The median age was 34
years (range 16-65). Sixty-five patients (20%) in the cohort
received high-risk BMTs; 159 (48.6%) underwent re l a t e d
allogeneic BMT, 133 (40.7%) underwent autologous BMT,
31 (9.5%) underwent URD BMT, and 4 (1.2%) underw e n t
syngeneic BMT for a variety of hematologic malignancies.
Of the 190 patients treated with related allogeneic or URD
B M T, GVHD prophylaxis consisted of T-cell depletion
with anti-CD5 antibody and complement (n 5 58; 30.5%),
cyclosporine A (CSA) and methotrexate (MTX) (n 5 1 2 4 ;
65.3%), or other regimens (n 5 8; 4.2%). Preparative re g i-
mens included cytosine arabinoside (ara-C), cyclophos-
phamide (Cy), and total-body irradiation (TBI) (n 5 1 5 6 ;
47.7%); busulfan (Bu) and Cy (n 5 41; 12.5%); Cy,
BCNU, and etoposide [CBV] (n 5 118; 36.1%); or other
regimens (n 5 12; 3.7%) as previously described [18-21].
PCP prophylaxis consisted of AP in 44 (13.4%) patients,
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TMP/SMX in 105 (32.1%) patients, dapsone in 31 (9.5%)
patients, and more than 1 regimen in 147 (45.0%) patients.
The median number of days on prophylaxis was less in the
AP group (121, range 21-902) compared with the other 3
g roups (TMP/SMX: 326 [2-1504]; dapsone: 321 [3-683];
m o re than 1 regimen: 332 [42-1326]). For those patients
alive at the time of analysis (December 31, 1994), the
median number of days receiving PCP prophylaxis was
similar: AP, 313; TMP/SMX, 365; dapsone, 365; more
than 1 regimen, 347.
Table 2 shows the breakdown of bone marrow transplant
type within each prophylaxis group. Approximately 40% of
patients in each group underwent autologous or syngeneic
B M T. Of the remaining 60% of patients receiving allogeneic
B M T, 16% (4/25) in the AP group and 17% (14/84) in the
m o re - t h a n - 1 - regimen group received URD BMT. This is in
contrast to the TMP/SMX and dapsone groups, in which
6% (4/62) and 47% (9/19), re s p e c t i v e l y, received URD
B M T. Patients receiving AP alone exhibited a higher pro b a-
bility of developing severe (defined as grade II or higher)
acute GVHD relative to those receiving TMP/SMX (OR
1.98 [95% CI 0.74, 5.36]), although the odds ratio did not
reach statistical significance. Patients receiving more than 1
regimen had a higher probability of developing chro n i c
GVHD than those receiving TMP/SMX alone (OR 1.62
[95% CI 0.83, 3.19]), also not statistically signific a n t .
Eight patients (2.4%) developed documented PCP
infection, 7 (2.1%) while receiving P carinii p ro p h y l a x i s .
The clinical characteristics of those patients who developed
PCP are displayed in Table 3. All 8 received an allogeneic
B M T. All but 1 developed some form of GVHD (2 acute
GVHD only, 2 chronic GVHD only, 3 both acute and
c h ronic GVHD). All 3 patients who developed PCP .1 year
after BMT had documented chronic GVHD. Two of these
3 patients were receiving P n e u m o c y s t i s p rophylaxis at the
time of infection. The median time from BMT to diagnosis
with PCP was 256 days for all 8 patients and 228 days for all
except 1 patient who developed PCP off prophylaxis. PCP
was a serious infectious complication post-BMT: 4 of
8 patients died from the infection.
Of the 7 patients on prophylaxis at the time of P n e u m o -
c y s t i s infection, 4 received only AP (4/44, 9.1%), 1 re c e i v e d
only dapsone (1/31, 3.2%), and 2 received more than 1 re g i-
men (2/147, 1.4%). Regarding the latter 2 patients, 1
received TMP/SMX for 65 days after BMT then AP for 131
days and contracted PCP. The other received dapsone or
TMP/SMX as prophylaxis for .16 months before develop-
ing PCP, although the patient received TMP/SMX for ,5
months. The patient developed PCP on dapsone, having
not received TMP/SMX for .11 months preceding the
diagnosis. None of the pat ients  who received only
TMP/SMX as prophylaxis developed PCP. As shown in
Table 4, the odds of acquiring PCP for the AP gro u p
relative to the TMP/SMX group were significantly higher
(OR 23.4 [95% CI 1.2, 445.2]), whereas the odds of acquir-
ing PCP for patients treated with dapsone or more than 1
regimen were not. This diff e rence was not explained by the
other 2 variables (number of treatment days on a pro p h y-
lactic regimen and type of BMT) that were considered for
inclusion in the model from the stepwise pro c e d u re. In fact,
the median number of days on prophylaxis was less for
those patients who developed PCP (243 days, range 93-
496) compared with those who did not develop PCP (321
days, range 2-1504). In addition, PCP infections occurre d
only in patients who received allogeneic BMT. In the analy-
sis of this cohort of patients, similar results were obtained:
the odds of acquiring PCP for the AP group relative to the
TMP/SMX group were significantly higher (OR 26.2 [CI
1.4, 506.2]).
F i g u re 1 illustrates the Kaplan-Meier survival pro b a b i l i t y
for each prophylaxis group. At 1 year post-BMT, survival for
the group receiving AP alone was 43.2% compared with
78.1% for those patients receiving only TMP/SMX. For
those patients receiving dapsone alone or more than 1 re g i-
men, the 1-year survival was 64.5% and 84.4%, re s p e ctively.
The probability of death at 1 year post-BMT for the AP
Table1. Patient Characteristics (n = 327)
n %
Sex
Men 169 51.7
Women 158 48.3
Age
Median 34
Range 16–65
Ethnic origin
African-American 2 0.6
Asian 4 1.2
Hispanic 11 3.4
White 310 94.8
Indication for BMT
Aplastic anemia 12 3.7
Acute lymphoblastic leukemia 8 2.4
Acute myelogenous leukemia 79 24.2
Chronic myelogenous leukemia 79 24.2
Hodgkin’s disease 47 14.4
Myelodysplasia 22 6.7
Non-Hodgkin’s lymphoma 77 23.5
Other 3 0.9
Transplant type
Related allogeneic 159 48.6
T cell–depleted 50 15.3
Not T cell–depleted 109 33.3
Unrelated allogeneic 31 9.5
T cell–depleted 8 2.5
Not T cell–depleted 23 7.0
Autologous 133 40.7
Syngeneic 4 1.2
GVHD (related allogeneic BMTs)
Acute
None/grade I 108 57.1
Grades II–IV 81 42.9
Not documented 1 0.5
Chronic 83 43.7
Preparative regimens
ara-C/Cy/TBI 156 47.7
Bu/Cy 41 12.5
CBV 118 36.1
Other 12 3.7
PCP prophylaxis regimens
AP 44 13.4
TMP/SMX 105 32.1
Dapsone 31 9.5
More than one regimen 147 45.0
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group relative to TMP/SMX was significant (OR 5.2 [95%
CI 2.4, 26.6]) after adjusting for sex, BMT type, and high-
risk BMT. Neither of the other 2 groups showed a signifi-
cant mortality risk relative to TMP/SMX (Table 4). The
p o o rer survival in the AP group continued beyond 1 year
p o s t - B M T; however, increasing numbers of censore d
patients made meaningful interpretation more difficult.
In other populations, such as cancer patients tre a t e d
with intensive chemotherapy regimens, TMP/SMX has
been shown to alter the risk of acquiring non-P n e u m o c y s t i s
infections [3,22-25]. Thus, the risk of acquiring other infec-
tions post-BMT was investigated among the 4 pro p h y l a x i s
g roups. As shown in Table 4, relative to the TMP/SMX
g roup, the probability of acquiring nonviral infections was
higher for both the AP group (OR 2.2 [95% CI 1.0, 4.6])
and the group receiving more than 1 regimen (OR 3.3 [95%
CI 1.9, 5.8]). In the group receiving dapsone alone, the
higher probability of nonviral infections after BMT was not
significant (OR 1.8 [95% CI 0.8, 4.3]). When only bacterial
infections were examined, only the group receiving more
than 1 regimen exhibited a higher probability of i n f e c t i o n
than the TMP/SMX group (OR 3.3 [95% CI 1.9, 5 . 8 ] ) .
F i n a l l y, the probability of developing fungal infections was
not increased in patients receiving TMP/SMX alone com-
pared with the other prophylaxis groups (Table 4).
Although the AP group exhibited an increased pro b a-
bility of developing PCP or other infections (excluding
viral infections) or dying at 1 year post-BMT relative to the
TMP/SMX group, treatment with AP was associated with
significantly fewer toxicities. For those patients re c e i v i n g
only AP, the probability of developing a tre a t m e n t - re l a t e d
toxicity was significantly less than those patients re c e i v i n g
only TMP/SMX (OR 0.2 [CI 0.04, 0.9]). To define the
s p e c t rum of complications necessitating discontinuation of
each prophylactic regimen, the toxicity profile for the
e n t i re cohort of 327 patients is re p o rted in Table 5. The
overall toxicity rate for any patient receiving AP was 7.5%.
In comparison, the toxicity rates were significantly gre a t e r
for TMP/SMX and dapsone—35.4% and 43%, re s p e c-
t i v e l y. As expected, the toxicity profile varied for each
agent. AP was associated primarily with re s p i r a t o ry and
g a s t rointestinal complaints. Although gastrointestinal com-
plaints were also seen with TMP/SMX and dapsone, bone
m a rrow suppression (cytopenia) and rash were much more
f requent toxicities. Dapsone was also associated with
hemolysis. Documented methemoglobinemia was re l a t i v e l y
Table 2. BMT Type of 327 Evaluable Patients by PCP Prophylactic Regimen
AP TMP/SMX Dapsone More than one regimen Total
n 44 105 31 147 327
BMT type
Autologous or syngeneic 19 (43.2) 43 (41.0) 12 (38.7) 63 (42.9) 137 (41.9)
Related allogeneic 21 (47.7) 58 (55.2) 10 (32.3) 70 (47.6) 159 (48.6)
URD 4 (9.1) 4 (3.8) 9 (29.0) 14 (9.5) 31 (9.5)
Data are n (%).
Table 3. Characteristics of Patients with PCP*
# days Alive/
Age post BMT deceased Cause
at time BMT Preparative GVHD Acute Chronic at time at time of of
Patient Diagnosis of BMT Sex type regimen* prophylaxis GVHD Grade GVHD of PCP analysis death
Cases with
AP as PCP
prophylaxis
1 AML 38 Female Related allogeneic Ara C/Cy/TBI T-cell depletion No NA No 284 Deceased PCP
2 CML 48 Female Related allogeneic Ara C/Cy/TBI T-cell depletion Yes II No 145 Deceased PCP
3 AML 22 Male Related allogeneic Bu/Cy MTX/CSA No NA Yes 187 Alive NA
4 CML 38 Male URD Ara C/Cy/TBI MTX/CSA Yes II No 136 Deceased PCP
Case with
dapsone as PCP
prophylaxis
5 AML 38 Male Related allogeneic Ara C/Cy/TBI MTX/CSA Yes I Yes 496 Alive NA
Cases with
more than one
prophylactic
regimen
6 ALL 25 Male Related allogeneic Ara C/Cy/TBI T-cell depletion No NA Yes 228 Alive NA
7 CML 34 Male URD Ara C/Cy/TBI MTX/CSA Yes III Yes 544 Deceased Suicide
Case occurring
while receiving
no PCP
prophylaxis
8 MDS 36 Male Related allogeneic Ara C/Cy/TBI T-cell depletion Yes II Yes 395 Deceased ARDS
*AML, acute myelogenous leukemia; ARDS, adult respiratory distress syndrome; CML chronic myelogenous leukemia; MDS, myelodysplasia; NA, not applicable.
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uncommon. All 3 regimens exhibited a low, but re l a t i v e l y
equivalent, incidence of noncompliance.
DISCUSSION
This large re t rospective cohort study of more than
300 bone marrow transplant patients examined the efficacy
of 3 standard regimens, AP, dapsone, and TMP/SMX, in
p reventing PCP following BMT. Toxicities necessitating
discontinuation of a particular regimen were also reviewed.
The 1-year mortality and probability of developing GVHD
or non-P n e u m o c y s t i s infection were examined in the 4 pro-
phylaxis groups identified: AP, dapsone, TMP/SMX, or
m o re than 1 regimen. Our analysis showed that patients
receiving only AP as P n e u m o c y s t i s p rophylaxis in the post-
BMT setting had a significantly higher probability of devel-
oping PCP than those patients receiving only TMP/SMX.
This observation is consistent with randomized data in the
H I V-positive population, where TMP/SMX has been
shown to be a superior primary prophylaxis to AP [8,26],
although not in all studies [27-29]. In the BMT population,
no randomized data re g a rding P n e u m o c y s t i s p rophylaxis are
available, although previous reports have suggested that AP
is an effective prophylactic agent, with no cases of PCP
re p o rted in 3 series totaling 96 patients [2,30,31]. These
findings differ substantially with the 9.1% (4/44) cumulative
incidence observed in our AP group, an incidence that
approaches what has been reported in the post-BMT setting
when no prophylaxis is administered [32]. Although AP dos-
ing regimens in these reports were similar to ours, patients
w e re treated with prophylaxis for either 100 days or 6 months
after BMT or 6 months after discontinuing immunosup-
p ression; 2 groups did not re p o rt follow-up beyond the
duration of treatment. The highest PCP risk post-BMT is
classically considered to occur within the first 6 months, but
that assessment is based primarily on early reports of infec-
tious complications post-BMT when P n e u m o c y s t i s p ro p h y-
laxis was either administered less vigorously [33] or not at all
[34]. The median time to diagnosis of infection after BMT
in our series was longer (256 days post-BMT). This time
frame may more accurately reflect the modern era of BMT,
w h e re prophylaxis is administered during the condition-
ing regimen as well as post-BMT, and patients at risk for
infection are those with complicating factors, such as
Table 4. Odds Ratios (95% CIs) of PCP, Mortality, and Infection Risk by Prophylaxis Group
TMP/SMX AP Dapsone More than one regimen
PCP 1.0 23.4 (1.2, 445.2) 10.4 (0.4, 261.3) 3.6 (0.2, 76.3)
1-year mortality 1.0 5.2 (2.4, 26.6) 1.7 (0.6, 4.6) 0.7 (0.3, 1.4)
All infections (excluding viral) 1.0 2.2 (1.0, 4.6) 1.8 (0.8, 4.3) 3.3 (1.9, 5.8)
All bacterial infections 1.0 1.9 (0.9, 4.1) 1.6 (0.6, 3.8) 3.3 (1.9, 5.8)
Fungal infections 1.0 0.8 (0.1, 4.6) 1.1 (0.2, 6.0) 0.7 (0.2, 2.5)
Figure 1. Kaplan-Meier curves showing the probability of survival by prophylaxis group.
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GVHD or prolonged steroid administration. A re c e n t
report confirms our observations [35].
Despite the increased effectiveness of TMP/SMX in
preventing PCP in our series, toxicities necessitating discon-
tinuation of TMP/SMX were markedly increased compared
with AP (35.4% versus 7.5%). The toxic ity rate for
TMP/SMX in our patient cohort was at least as great as that
reported in HIV-positive patients [8,26,27], with bone mar-
row suppression and rash being the most frequent. Dapsone
exhibited even higher toxicity rates, with hemolysis being of
g reatest concern. As noted pre v i o u s l y, diff e rences in the
p robability of developing severe acute GVHD or chro n i c
GVHD were observed among the prophylactic gro u p s ,
although none were significant. Whether these diff e re n c e s
account for the diff e rences in tre a t m e n t - related toxicity
among the 4 treatment groups cannot be assessed, given the
relatively small number of patients with severe acute or
chronic GVHD in the entire cohort. 
F o rty-five percent (147/327) of the patient cohort
received more than 1 prophylactic regimen. One might
hypothesize that, although they were clearly a hetero g e-
neous group, the bulk of these patients were those with pro-
phylaxis-associated toxicities. However, 80 patients (54%)
in this group received only AP or dapsone pre c e d i n g
TMP/SMX. At our center, Pneumocystis prophylaxis is often
initiated with either of these 2 drugs because they are not
associated with bone marrow toxicity. TMP/SMX is insti-
tuted within days or weeks once bone marrow engraftment
i m p roves. A third consideration is that the complications
observed in this group (cytopenias, rashes, or pulmonary or
gastrointestinal symptoms) were unrelated to their Pneumo -
c y s t i s p rophylaxis but instead were manifestations of other
entities such as GVHD, other infections, or bone marro w
rejection, which would suggest a more ill group overall.
Data in Figure 1 do not support this hypothesis, however,
since no significant survival diff e rence was identified
between this group and those receiving TMP/SMX alone.
The probability of this group acquiring bacterial infections
c o m p a red with the TMP/SMX group was significantly
higher (Table 4). Whether this difference was due to a rela-
tive lack of treatment with TMP/SMX is not clear. Regard-
less, from our analysis it appears that this group is primarily
composed of 2 types of patients: those who received AP or
dapsone before TMP/SMX at the time of discharge fro m
their BMT and those with prophylaxis-associated toxicities.
No data from our analysis suggest that this is an inherently
sicker patient population.
GVHD and infection, along with relapse of the patient ’s
underlying disease, are the most common complications
following BMT. Thus, we examined whether the pro p h y-
lactic regimen administered affected either outcome. The
p robability of developing GVHD was similar for all of the
g roups. In contrast, patients receiving AP alone or more
than 1 regimen exhibited significantly higher odds of
acquiring nonviral infections compared with those re c e i v-
ing only TMP/SMX, whereas the odds of developing non-
viral infections were similar in patients receiving either
dapsone or TMP/SMX. As previously noted, this finding
c o n f i rms data from other patient populations where pro-
phylactic TMP/SMX is associated with a decreased inci-
dence of infections. Both TMP/SMX and dapsone have
been associated with decreased rates of infection with To x o -
plasma gondii in HIV-positive patients; the small number of
documented cases of toxoplasmosis in our cohort (n 5 1 )
p recludes our ability to comment on our BMT population.
F i n a l l y, we observed no increased probability of fungal
infections in the TMP/SMX group compared with the
other 3, a potential theoretical concern with pro l o n g e d
antibiotic use in this population.
P e rhaps the most striking observation from our analysis
was the marked increased probability of death at 1 year post-
BMT for the AP group compared with TMP/SMX, even
when adjusted for variables such as type of BMT and sex.
The probability of developing other infections was signifi-
cantly higher in this group, possibly contributing to this
finding. However, patients given more than 1 regimen exhib-
ited a 1-year mortality comparable to those re c e i v i n g
TMP/SMX, despite a higher probability of infections.
We conclude that TMP/SMX is more effective than AP
in preventing PCP in the post-BMT setting and is associ-
ated with a decreased probability of developing nonviral
infections compared with other regimens. For reasons not
entirely obvious, AP was associated with increased mortality
at 1 year post-BMT compared with TMP/SMX. Thus,
despite its increased toxicities relative to AP, our data sup-
port TMP/SMX as the preferable prophylactic agent in this
patient population. In all cases, when PCP was diagnosed, it
occurred much later than has been previously reported fol-
lowing BMT. Thus, our data support P carinii p ro p h y l a x i s
for 1 year from the date of BMT, and indefinitely in the set-
ting of chronic GVHD or prolonged corticosteroid use for
other reasons. Dapsone was not associated with a significant
i n c reased probability of PCP infection or death compare d
with TMP/SMX. Thus, despite its significant rate of toxici-
ties, it should represent second-line prophylaxis in this pop-
ulation. Prospective randomized trials including newer
agents such as atovaquone [36], but not AP, should be con-
sidered to confirm these results, especially in patients intol-
erant of TMP/SMX.
Table 5. Prophylaxis-associated Toxicities
AP TMP/SMX Dapsone
No. patients* 133 240 114
Azotemia — 4 (1.7) 1 (0.9)
Cytopenia — 37 (15.4) 6 (5.3)
Eosinophilia — 3 (1.2) —
Fever — 4 (1.7) —
Hemolysis — 1 (0.4) 24 (21.0)
Hepatitis — 1 (0.4) —
Methemoglobinemia — — 3 (2.6)
Nausea/vomiting 2 (1.5) 8 (3.3) 3 (2.6)
Noncompliance 3 (2.2) 6 (2.5) 1 (0.9)
Rash 1 (0.8) 21 (8.8) 11 (9.6)
Respiratory 4 (3.0) — —
Any toxicity 10 (7.5) 85 (35.4) 49 (43.0)
Data are n (%). Prophylaxis-associated toxicity is defined as any toxicity
deemed severe enough by the treating clinician to discontinue that particular
regimen. 
*Number exceeds 327 because 147 patients received more than one prophylaxis
regimen.
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